お知らせ
CMS Announces 15 Additional Drugs Selected for Medicare Drug Price Negot iations in Continued Effort to Lower Prescription Drug Costs for Seniors
- [登録者]Centers for Medicare & Medicaid Services (CMS)
- [言語]日本語
- [エリア]Baltimore, MD
- 登録日 : 2025/01/17
- 掲載日 : 2025/01/17
- 変更日 : 2025/01/17
- 総閲覧数 : 4 人
- お店を検索するなら『タウンガイド』
-
- 2月4日新学期開始!・ご注意:ワシントンDCエリアに校舎はありません。SAPIX...
-
あの「SAPIX」の授業がアメリカにいても受講できるんです!しかも!日本のSAPIXとは一味違う「SAPIX USA」の授業がグレーターワシントンDCでも受講できるんです!日本への進学・受験ならば、サピックスにお任せください。ニューヨーク校、ニュージャージー校、マンハッタン校、サンノゼ校の授業がオンラインで受講できます!ご注意:ワシントンDCエリアに校舎はありません。ニューヨーク校などのオンライン...
+1 (914) 358-5337SAPIX USA
-
- 全米で日本語を話す医療者と患者をつなぎ、日本人コミュニティに向けた医療情報やサポ...
-
「FLAT・ふらっと」は、ニューヨークを拠点に全米で活動する非営利団体で、日本語を話す医療者と患者をつなぎ、日本人コミュニティをサポートしています。アメリカでの医療や保険の複雑さに直面する日本人やその介護者、高齢化に伴い孤立するシニアが増加する中、私たちは必要な情報やサポートを提供しています。オンライン活動も活発に行っており、ニューヨーク以外にお住まいの方でも気軽にご参加いただけます。健康に関する...
+1 (772) 349-9459FLAT ・ふらっと
-
- ワシントンDC・バージニア州・メリーランド州・コネチカット州のかかりつけクリニッ...
-
日本を離れ、米国で暮らしている方々にとって、最も心配かつ重要なことは自分や家族の健康のことです。ニュージャージーに位置する当クリニックでは、内科、小児科、外科、婦人科、皮膚科、眼科、耳鼻咽喉科など、あらゆる診療科に対応しています。この度、ひばりファミリーメディカルでは、ニュージャージー州に加え、ワシントンDC、バージニア州、メリーランド州、コネチカット州での遠隔診療を開始致しました。遠隔にお住まい...
+1 (201) 581-8553ひばりファミリーメディカル
-
- 精神科・心療内科医 松木隆志のDCオフィスへようこそ ワシントンD.C.全域にお...
-
転勤、留学、国際結婚などの様々な理由で毎年数多くの日本人が米国にやってきますが、そのうちの多くの方々が異国での慣れない生活、新しい仕事や学校への不適応、文化や言葉の壁、日本の家族や友人との離別など様々なストレスにさらされています。強いストレスは様々なこころの不調を引き起こします。こんな症状はありますか?気分の落ち込み、倦怠感、疲労感、喜びの消失、興味の消失、孤独感、焦燥感、罪悪感、空虚感、食欲減退...
+1 (201) 809-3508精神科・心療内科医 松木隆志
January 17, 2025
*"CMS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations in Continued Effort to Lower Prescription Drug Costs for Seniors"*
Today, the Centers for Medicare & Medicaid Services (CMS), announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027. Between November 2023 and October 2024, about 5.3 million people with Medicare Part D coverage used these drugs to treat a variety of conditions, such as cancer and type 2 diabetes. These selected drugs accounted for about $41 billion in total gross covered prescription drug costs under Medicare Part D, or about 14%, during that time period. When combined with the total gross covered prescription drug costs under Medicare Part D of the 10 drugs selected for the first cycle of negotiations over that same time period, this represents over a third of total gross covered prescription drug costs under Medicare Part D.
The selected drug list for the second cycle of negotiations is:
* Ozempic; Rybelsus; Wegovy
* Trelegy Ellipta
* Xtandi
* Pomalyst
* Ibrance
* Ofev
* Linzess
* Calquence
* Austedo; Austedo XR
* Breo Ellipta
* Tradjenta
* Xifaxan
* Vraylar
* Janumet; Janumet XR
* Otezla
View a CMS fact sheet on the drugs selected for the Medicare Drug Price Negotiation Program at: https://www.cms.gov/files/document/factsheet-medicare-negotiation-selected-drug-list-ipay-2027.pdf
More information on the Medicare Drug Price Negotiation Program is available at https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation.
*"Negotiation Data Elements and Drug Price Negotiation Process ICR Approved "*
The Negotiation Data Elements and Drug Price Negotiation Process approved ICR is available for viewing on OMB’s website [ https://www.reginfo.gov/public/do/PRAViewICR?ref_nbr=202411-0938-010 ]. Click “all” to see full details. For initial price applicability year 2027, data submissions from participating drug companies of the selected drugs must be provided to CMS by March 1, 2025. Members of the public may also submit evidence about the selected drugs and their alternative treatments by March 1, 2025, via a web link that will be available through CMS.gov after the selected drug list is published. For initial price applicability year 2027, CMS will issue an initial written offer no later than June 1, 2025 and statutory written counteroffers, if applicable, will be due from participating manufacturers of the selected drugs 30 days after receipt of the initial offer.
Blue abstract shape.
________________________________________________________________________
You're getting this message because you subscribed to get email updates from the Centers for Medicare & Medicaid Services (CMS) [ http://www.cms.gov/ ].
Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page [ https://public.govdelivery.com/accounts/USCMS/subscriber/edit?preferences=true#tab1 ]. You will need to use your email address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com [ https://subscriberhelp.govdelivery.com/ ].
This service is provided to you at no charge by Centers for Medicare & Medicaid Services (CMS) [ http://www.cms.gov ].
________________________________________________________________________
This email was sent to mshinji3056@gmail.com using GovDelivery Communications Cloud 7500 Security Boulevard · Baltimore MD 21244
body .abe-column-block { min-height: 5px; } table.gd_combo_table img {margin-left:10px; margin-right:10px;} table.gd_combo_table div.govd_image_display img, table.gd_combo_table td.gd_combo_image_cell img {margin-left:0px; margin-right:0px;} table.govd_hr {min-width: 100%;}